EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Tibolone Use Associated With Elevated Hepatocellular Carcinoma Risk: Findings From a Nationwide Cohort

Jimin Lee, Hye Jun Kim, Sun Jae Park, Sangwoo Park, Jina Chung, Jiwon Yu, Ju Hyun Kang, Seogsong Jeong, Hyun‐Young Shin, Sang Min Park

International Journal of Cancer · 2027-01-01 · 160 (1) · 24-30

DOI: 10.1002/ijc.70725 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Tibolone, a synthetic steroid with estrogenic, progestogenic, and androgenic activity, is widely prescribed for menopausal symptoms, but its association with hepatocellular carcinoma (HCC) remains unclear. Using data from 117,271 women aged ≥ 45 years in the Korean National Health Insurance Service–Health Screening Cohort, we evaluated tibolone use between 2003 and 2007 and identified incident HCC from 2009 through 2019, implementing a 1‐year lag period. Participants were propensity score–matched (1:10) by demographic, lifestyle, and metabolic factors. During a median 11‐year follow‐up, women with ≥ 180 cumulative days of tibolone use showed a higher HCC risk compared with non‐users (hazard ratio [HR], 1.88; 95% CI, 1.07–3.29), which persisted after adjustment for key covariates (adjusted hazard ratio [aHR], 1.74; 95% CI, 0.99–3.06). A dose–response trend was observed ( P for trend = 0.043). These findings suggest a possible link between sustained tibolone use and HCC risk, warranting confirmation in larger populations and longer follow‐up, ideally through well‐designed prospective studies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →